Results 211 to 220 of about 8,834,434 (252)

Cohort profile: the provincial opioid agonist treatment cohort in Ontario, Canada. [PDF]

Eur J Epidemiol
Morin KA, Tatangelo MR, Acharya S, Marsh DC.   +3 more
europepmc   +1 more source

Identifying opioid agonist treatment prescriber networks from health administrative data: A validation study. [PDF]

PLoS One
Kurz M, Tatangelo M, Morin KA, Zanette M, Krebs E, Marsh DC, Nosyk B.   +6 more
europepmc   +1 more source

Correction: Psychiatrist-led hepatitis C (HCV) treatment at an opioid agonist treatment clinic in Stockholm- a model to enhance the HCV continuum of care. [PDF]

BMC Psychiatry
Klasa PE, Sandell M, Aleman S, Kåberg M.   +3 more
europepmc   +1 more source

Targeting CXCR2 in Nociceptive Sensory Neurons Offers Novel Therapeutic Potentials for Postoperative Pain

Advanced Science, Volume 13, Issue 61, 3 November 2026.
Tissue incision induces CXCL5 release, which activates neuronal CXCR2 on incision‐innervating sensory neurons. Neuronal CXCR2 couples with TRPA1 to drive mechanical pain and engages p38 MAPK signaling to upregulate TRPV1 and promote heat pain. Targeted Cxcr2 knockdown relieves incisional pain while preserving CXCR2‐dependent neutrophil responses ...
Yushuang Pan, Peiyi Li, Yufeng Chen, Zishan Dong, Yuanyuan Li, Boyu Liu, Yan Tai, Chuan Wang, Jianqiao Fang, Chengyu Yin, Boyi Liu   +10 more
wiley   +1 more source

Comparative effectiveness of urine drug testing schedules alongside opioid agonist treatment: Emulation of a population-based target trial in British Columbia, Canada. [PDF]

Addiction
Kurz M, Guerra-Alejos BC, Min JE, Seaman SR, Piske M, Bach P, Bruneau J, Greenland S, Gustafson P, Kampman K, Karim ME, Korthuis PT, Platt RW, Siebert U, Socías ME, Wood E, Nosyk B.   +16 more
europepmc   +1 more source

Comparative Effectiveness of GLP‐1RAs, SGLT2is and DPP4is for Cardiovascular Outcomes in Type 2 Diabetes: An Empirically Calibrated Target Trial Emulation Study

Diabetes, Obesity and Metabolism, Volume 28, Issue 12, Page 11971-11977, December 2026.
Bingyu Zhang, Ting Zhou, Huilin Tang, Yiwen Lu, Dazheng Zhang, Jiajie Chen, Tianchu Lyu, Kai Zheng, David A. Asch, Yong Chen   +9 more
wiley   +1 more source

ZBTB18 Dysfunction Promotes Neuropathic Pain via CHD4‐based Epigenetic Disinhibition of CLIC1 Channels in Sensory Neurons

Advanced Science, Volume 13, Issue 63, 12 November 2026.
In this study, we identify a novel functional role of ZBTB18 in regulating trigeminal‐mediated neuropathic pain. Nerve injury reduces ZBTB18 in trigeminal ganglion neurons, impairing CHD4/NuRD recruitment and de‐repressing Clic1. Elevated CLIC1 enhances chloride channel activity and neuronal hyperexcitability, thereby driving pain.
Shoupeng Wang, Zitong Huang, Yu Tao, Yunmei Zhang, Yufang Sun, Dongsheng Jiang, Weiwei Lu, Fuhai Ji, Gang Chen, Min Xu, Yuan Zhang, Jin Tao   +11 more
wiley   +1 more source

Initiation of opioid agonist treatment following hospital-treated opioid toxicities and the risk of repeat events in Ontario, Canada: a cohort study using inverse probability of treatment weights. [PDF]

BMJ Public Health
Ledlie S, Tadrous M, Bayoumi AM, McCormack D, Kent JT, Besharah J, Munro C, Gomes T.   +7 more
europepmc   +1 more source

Development of a nalmefene formulation suitable for a community‐use auto‐injector

British Journal of Clinical Pharmacology, Volume 92, Issue 11, Page 3914-3925, November 2026.
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano, Manjunath S. Shet, Hugh Huang, Ronnie Ortiz, Garth T. Whiteside, Glen Apseloff, Stephen C. Harris   +6 more
wiley   +1 more source